- FDA: ~ "about the imbalance of cardiac events, we cannot exclude Heplisav as cause" - There's the uncertainty of the baysian analysis by FDA statisticians - The FDA and DVAX still are discussing about the postmarketing study (p.45), since the first they weren't so happy about the first proposal
I do not have any DVAX share now, since the decision is too uncertain to me. Perhaps I will overpay when buying back some DVAX shares after a positive FDA vote (since I like their IO stuff). Perhaps I just avoided a loss.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.